CULLINAN THERAPEUTICS, INC. Income Taxes Paid
CULLINAN THERAPEUTICS, INC. (CGEM) reported Income Taxes Paid of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2025-12-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2025-09-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2025-06-30 was -$2.97M, a 286.09% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2025-03-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. income taxes paid, net for fiscal 2025 was -$2.97M.
- CULLINAN THERAPEUTICS, INC. income taxes paid, net for fiscal 2024 was -$2.27M.
- CULLINAN THERAPEUTICS, INC. income taxes paid, net for fiscal 2023 was -$4.43M, a 111.73% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. income taxes paid, net for fiscal 2022 was $37.80M.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | -$2.97M derived: sum of 3 quarters · filed 2026-08-06 | -$2.97M 10-K · filed 2026-03-10 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.97M derived: sum of 2 quarters · filed 2026-08-06 | -$2.97M 10-Q · filed 2025-11-06 | -$2.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.97M 10-Q · filed 2026-08-06 | -$2.97M derived: sum of 3 quarters · filed 2026-08-06 | -$2.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $0.00 derived: sum of 3 quarters · filed 2026-03-10 | $1.60M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $1.60M derived: sum of 3 quarters · filed 2026-03-10 | -$2.27M 10-K · filed 2026-03-10 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.60M derived: sum of 2 quarters · filed 2025-11-06 | -$2.27M 10-Q · filed 2025-11-06 | -$11.41M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.27M 10-Q · filed 2025-08-07 | -$11.41M derived: sum of 3 quarters · filed 2025-08-07 | -$11.41M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$3.87M 10-Q · filed 2025-05-08 | -$13.01M derived: sum of 2 quarters · filed 2025-05-08 | -$13.01M derived: sum of 3 quarters · filed 2025-05-08 | -$8.38M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$9.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$9.14M derived: sum of 2 quarters · filed 2025-02-27 | -$4.51M derived: sum of 3 quarters · filed 2025-02-27 | -$4.43M 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.63M derived: sum of 2 quarters · filed 2024-11-07 | $4.71M 10-Q · filed 2024-11-07 | $9.93M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $4.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.71M 10-Q · filed 2024-08-08 | $9.93M derived: sum of 3 quarters · filed 2024-08-08 | $42.51M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $75.00K 10-Q · filed 2024-05-15 | $5.29M derived: sum of 2 quarters · filed 2024-05-15 | $37.88M derived: sum of 3 quarters · filed 2024-05-15 | $37.88M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $5.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $37.80M derived: sum of 2 quarters · filed 2024-03-14 | $37.80M derived: sum of 3 quarters · filed 2024-03-14 | $37.80M 10-K · filed 2024-03-14 |
| 2022-09-30 | $32.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $32.58M derived: sum of 2 quarters · filed 2023-11-08 | $32.58M 10-Q · filed 2023-11-08 | $32.58M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2023-08-10 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |